212 related articles for article (PubMed ID: 35014767)
1. The Sec61 translocon is a therapeutic vulnerability in multiple myeloma.
Domenger A; Choisy C; Baron L; Mayau V; Perthame E; Deriano L; Arnulf B; Bories JC; Dadaglio G; Demangel C
EMBO Mol Med; 2022 Mar; 14(3):e14740. PubMed ID: 35014767
[TBL] [Abstract][Full Text] [Related]
2. Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma.
Domenger A; Ricci D; Mayau V; Majlessi L; Marcireau C; Dadaglio G; Demangel C
Front Oncol; 2023; 13():1110916. PubMed ID: 36776330
[TBL] [Abstract][Full Text] [Related]
3. Proteomics Reveals Scope of Mycolactone-mediated Sec61 Blockade and Distinctive Stress Signature.
Morel JD; Paatero AO; Wei J; Yewdell JW; Guenin-Macé L; Van Haver D; Impens F; Pietrosemoli N; Paavilainen VO; Demangel C
Mol Cell Proteomics; 2018 Sep; 17(9):1750-1765. PubMed ID: 29915147
[TBL] [Abstract][Full Text] [Related]
4. Biochemical and Biological Assays of Mycolactone-Mediated Inhibition of Sec61.
O'Keefe S; High S; Demangel C
Methods Mol Biol; 2022; 2387():163-181. PubMed ID: 34643911
[TBL] [Abstract][Full Text] [Related]
5. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
6. Mycolactone enhances the Ca2+ leak from endoplasmic reticulum by trapping Sec61 translocons in a Ca2+ permeable state.
Bhadra P; Dos Santos S; Gamayun I; Pick T; Neumann C; Ogbechi J; Hall BS; Zimmermann R; Helms V; Simmonds RE; Cavalié A
Biochem J; 2021 Nov; 478(22):4005-4024. PubMed ID: 34726690
[TBL] [Abstract][Full Text] [Related]
7. Non-lethal proteasome inhibition activates pro-tumorigenic pathways in multiple myeloma cells.
Skorda A; Sklirou AD; Sakellaropoulos T; Gianniou DD; Kastritis E; Terpos E; Tsitsilonis OE; Florea BI; Overkleeft HS; Dimopoulos MA; Alexopoulos LG; Trougakos IP
J Cell Mol Med; 2019 Dec; 23(12):8010-8018. PubMed ID: 31568628
[TBL] [Abstract][Full Text] [Related]
8. Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition.
Bennett MK; Li M; Tea MN; Pitman MR; Toubia J; Wang PP; Anderson D; Creek DJ; Orlowski RZ; Gliddon BL; Powell JA; Wallington-Beddoe CT; Pitson SM
Neoplasia; 2022 Jan; 24(1):1-11. PubMed ID: 34826777
[TBL] [Abstract][Full Text] [Related]
9. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
[TBL] [Abstract][Full Text] [Related]
10. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress.
Wallington-Beddoe CT; Bennett MK; Vandyke K; Davies L; Zebol JR; Moretti PAB; Pitman MR; Hewett DR; Zannettino ACW; Pitson SM
Oncotarget; 2017 Jul; 8(27):43602-43616. PubMed ID: 28467788
[TBL] [Abstract][Full Text] [Related]
11. Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma.
Ferguson ID; Lin YT; Lam C; Shao H; Tharp KM; Hale M; Kasap C; Mariano MC; Kishishita A; Patiño Escobar B; Mandal K; Steri V; Wang D; Phojanakong P; Tuomivaara ST; Hann B; Driessen C; Van Ness B; Gestwicki JE; Wiita AP
Cell Chem Biol; 2022 Aug; 29(8):1288-1302.e7. PubMed ID: 35853457
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells.
Chauhan D; Tian Z; Zhou B; Kuhn D; Orlowski R; Raje N; Richardson P; Anderson KC
Clin Cancer Res; 2011 Aug; 17(16):5311-21. PubMed ID: 21724551
[TBL] [Abstract][Full Text] [Related]
13. Anti-tumor activity of the proteasome inhibitor BSc2118 against human multiple myeloma.
Zang M; Li Z; Liu L; Li F; Li X; Dai Y; Li W; Kuckelkorn U; Doeppner TR; Hermann DM; Zhou W; Qiu L; Jin F
Cancer Lett; 2015 Oct; 366(2):173-81. PubMed ID: 26116344
[TBL] [Abstract][Full Text] [Related]
14. A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells.
Milan E; Perini T; Resnati M; Orfanelli U; Oliva L; Raimondi A; Cascio P; Bachi A; Marcatti M; Ciceri F; Cenci S
Autophagy; 2015; 11(7):1161-78. PubMed ID: 26043024
[TBL] [Abstract][Full Text] [Related]
15. Mechanistic insights into the inhibition of Sec61-dependent co- and post-translational translocation by mycolactone.
McKenna M; Simmonds RE; High S
J Cell Sci; 2016 Apr; 129(7):1404-15. PubMed ID: 26869228
[TBL] [Abstract][Full Text] [Related]
16. The One That Got Away: How Macrophage-Derived IL-1β Escapes the Mycolactone-Dependent Sec61 Blockade in Buruli Ulcer.
Hall BS; Hsieh LT; Sacre S; Simmonds RE
Front Immunol; 2021; 12():788146. PubMed ID: 35154073
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibitor therapy in multiple myeloma.
Chauhan D; Hideshima T; Mitsiades C; Richardson P; Anderson KC
Mol Cancer Ther; 2005 Apr; 4(4):686-92. PubMed ID: 15827343
[TBL] [Abstract][Full Text] [Related]
18. Sec61 blockade by mycolactone: A central mechanism in Buruli ulcer disease.
Demangel C; High S
Biol Cell; 2018 Nov; 110(11):237-248. PubMed ID: 30055020
[TBL] [Abstract][Full Text] [Related]
19. Structure of the Inhibited State of the Sec Translocon.
Gérard SF; Hall BS; Zaki AM; Corfield KA; Mayerhofer PU; Costa C; Whelligan DK; Biggin PC; Simmonds RE; Higgins MK
Mol Cell; 2020 Aug; 79(3):406-415.e7. PubMed ID: 32692975
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitors.
Prelowska MK; Mehlich D; Ugurlu MT; Kedzierska H; Cwiek A; Kosnik A; Kaminska K; Marusiak AA; Nowis D
Cancer Lett; 2021 Jun; 507():13-25. PubMed ID: 33713737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
